Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ametinib plus carbamazepine with intrathecal pemetrexed for symptomatic epilepsy in EGFR-mutant lung cancer leptomeningeal metastases
ChiCTR2300070038Phase 2Not yet recruiting
- Sponsor
- The 2nd Affiliated Hospital of Harbin Medical University
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in Secondary epilepsy, Carcinomatous Meningitis (CM) and Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by The 2nd Affiliated Hospital of Harbin Medical University. Primary endpoints: Overall survival and Control rate of epilepsy. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
03
Conditions
Secondary epilepsyCarcinomatous Meningitis (CM)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300070038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070038.